Recombinant alpha-1-microglobulin: a potential treatment for preeclampsia
| Autor: | Stefan R. Hansson, Magnus Gram, Rolf Gunnarsson, Bo Åkerström |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Placenta Endogeny law.invention Preeclampsia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pre-Eclampsia Pregnancy law Internal medicine Alpha-Globulins Drug Discovery Fetal hemoglobin medicine Animals Humans Heme reproductive and urinary physiology Pharmacology 030219 obstetrics & reproductive medicine business.industry medicine.disease Recombinant Proteins female genital diseases and pregnancy complications 030104 developmental biology medicine.anatomical_structure Endocrinology chemistry embryonic structures Immunology Recombinant DNA Female Alpha-1-microglobulin business |
| Zdroj: | Drug Discovery Today. 22:736-743 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2016.12.005 |
| Popis: | Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the potential to become the first specific therapy for preeclampsia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect